Author

Christopher Wilson

Primary ORCID profile (0000-0002-8012-2440 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Christopher WilsoniD1 paper · Howard Hughes Medical Institute

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1

Frequent Co-Authors

Abhijith Kundadka KudvaiD· 1 shared Alireza RezaniaiD· 1 shared Arnav ChhabraiD· 1 shared Christopher S. CheniD· 1 shared Christopher Steele· 1 shared Corin V. White· 1 shared David J. Broderick· 1 shared Eric J. VanderploegiD· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Abhijith Kundadka KudvaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Expandable, Functional Hepatocytes Derived from Primary Cells Enable Liver Therapeutics

Sunil K. Mallanna, Soujanya S. Karanth, Joseph E. Marturano, Abhijith Kundadka Kudva, Marcus Lehmann, Julie K. Morse, Morgan Jamiel, Timothy J. Norman, Christopher Wilson, Fabiola Munarin, David J. Broderick, Maxwell Van Buskirk, Esha A. Uddin, Michael Ret, Christopher Steele, , Arnav Chhabra

This study develops a scalable method to expand primary human hepatocytes while preserving their function, enabling improved liver cell therapy.

bioRxiv · Dec 28, 2024 · PreprintBioengineering

Repurposing the quinoline antibiotic nitroxoline to treat infections caused by the brain-eating amoeba Balamuthia mandrillaris

Matthew T. Laurie, Corin V. White, Hanna Retallack, Wesley Wu, Matthew S. Moser, Judy Sakanari, Kenny Ang, Christopher Wilson, Michelle R. Arkin, Joseph L. DeRisi

This paper identifies nitroxoline as a potent inhibitor of Balamuthia mandrillaris, showing greater efficacy than current treatments for granulomatous amoebic encephalitis.

bioRxiv · Jun 6, 2018 · PreprintPharmacology & Toxicology